nmsg

Licensing and alliances

Thanks to its consolidated wide know how in oncology research and its technological platforms, NMS Group is interested building strategic alliances and partnerships in order to promote the discovery and development of new innovative treatments for cancer.

In particular, NMS Group is involved in licensing specific projects in different development stages - both preclinical and clinical - and in implementing cooperation initiatives in R&D area.

In these recent years the Centre has capitalized its discoveries in international agreements with most representative pharmaceutical and biotech companies worldwide and signed the following deals:

MediaPharma Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugate

Oxford BioTherapeutics Licenses Nerviano Medical Sciences’ Drug-Linker Technology to Develop Novel Antibody Drug Conjugates

Tiziana Life Sciences licenses milciclib from Nerviano Medical Sciences

Ignyta and Nerviano announce license agreement for two first-in-class kinase inhibitors

Cellectis and Accelera (Nerviano Medical Sciences Group) sign an agreement to complete preclinical studies of Cellectis lead product candidate UCART19

Nerviano Medical Sciences signs a license agreement with the American biotechnology company Ignyta for two leading tyrosine kinase inhibitors

Accelera (Nerviano Medical Sciences Group) selected by Karolinska Development as preferred provider for pre-clinical research and signs a framework agreement for the supply of services

Nerviano Medical Sciences and Servier announce a collaboration and license agreement for a novel anticancer drug

Nerviano Medical Sciences announces new license agreement with Novartis

Nerviano Medical Sciences announces a new license agreement with Genentech for small molecule inhibitors

Nerviano Medical Sciences announces a new collaboration agreement with Genentech to discover antibody drug conjugates

Nerviano Medical Sciences and Genentech joint strenghts

Nerviano Medical Sciences expands partnership with ChemDiv in lead discovery

Brostallicin, the new oncology drug candidate, discovered by NMS was licensed to CTI

Agreement with BRISTOL-MYERS SQUIBB

 
To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.